178 related articles for article (PubMed ID: 19706990)
1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.
Iwamoto K; Nasu R; Yamamura A; Kothare PA; Mace K; Wolka AM; Linnebjerg H
Endocr J; 2009; 56(8):951-62. PubMed ID: 19706990
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
4. Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
Trautmann ME; Van Gaal L; Han J; Hardy E
J Diabetes Complications; 2017 Sep; 31(9):1415-1422. PubMed ID: 28669463
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
[TBL] [Abstract][Full Text] [Related]
7. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
Wysham CH; MacConell L; Hardy E
Diabetes Care; 2016 Oct; 39(10):1768-76. PubMed ID: 27436275
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Henry RR; Logan D; Alessi T; Baron MA
Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.
Cui YM; Guo XH; Zhang DM; Tham LS; Tang CC; Mace K; Linnebjerg H
J Diabetes; 2013 Jun; 5(2):127-35. PubMed ID: 23332026
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
Kothare PA; Linnebjerg H; Isaka Y; Uenaka K; Yamamura A; Yeo KP; de la Peña A; Teng CH; Mace K; Fineman M; Shigeta H; Sakata Y; Irie S
J Clin Pharmacol; 2008 Dec; 48(12):1389-99. PubMed ID: 19047364
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
Henry RR; Klein EJ; Han J; Iqbal N
Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
[TBL] [Abstract][Full Text] [Related]
13. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
[TBL] [Abstract][Full Text] [Related]
16. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Jabbour SA; Frías JP; Ahmed A; Hardy E; Choi J; Sjöström CD; Guja C
Diabetes Care; 2020 Oct; 43(10):2528-2536. PubMed ID: 32816874
[TBL] [Abstract][Full Text] [Related]
18. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Nelson P; Poon T; Guan X; Schnabel C; Wintle M; Fineman M
Diabetes Technol Ther; 2007 Aug; 9(4):317-26. PubMed ID: 17705687
[TBL] [Abstract][Full Text] [Related]
19. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
